Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced it has begun testing MB-204 in the Oprm 1 m odel of autism in collaboration with Dr. Julie Le Merrer and Dr. Jer e Becker at the iBrain Institute, Tours, France. The company seen immediate effects of MB-204 after a single dose in mouse models of depression, which gives confidence the drug could offer improvements in these autistic behaviours after a short course therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 CAD | +11.11% | -13.04% | +25.00% |
1st Jan change | Capi. | |
---|---|---|
+25.00% | 2.92M | |
+44.48% | 55.07B | |
+44.19% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- MRVL Stock
- News Marvel Biosciences Corp.
- Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Testing MB-204 on Autism by French University